Glossary

Design-Make-Test-Analyze Cycle

The Design-Make-Test-Analyze (DMTA) cycle is the core iterative workflow in modern drug discovery where computational molecular design, chemical synthesis, biological testing, and data-driven analysis inform each successive round of compound optimization.

Get in touch Learn more

Finance analyst reviewing cash flow AI optimization on laptop, charts and projections visible, home office work session.

DMTA CYCLE

What is the Design-Make-Test-Analyze Cycle?

The Design-Make-Test-Analyze (DMTA) cycle is the iterative, closed-loop engine of modern drug discovery, systematically refining molecular candidates through successive rounds of computational design, chemical synthesis, biological assay, and data-driven analysis.

The Design-Make-Test-Analyze (DMTA) cycle is the foundational iterative workflow in medicinal chemistry that drives lead optimization. It begins with the Design phase, where computational models propose molecular modifications to improve potency, selectivity, or ADMET properties. The Make phase involves synthesizing the designed compounds, followed by the Test phase, where they undergo rigorous biological and physicochemical assays. The cycle closes with the Analyze phase, where the resulting data refines predictive models and informs the next design hypothesis.

The primary goal of the DMTA cycle is to accelerate the convergence on a clinical candidate by systematically reducing uncertainty. Each loop generates critical structure-activity relationship (SAR) data, transforming the process from a linear sequence into a knowledge-generating engine. Modern AI integration, including active learning and Bayesian optimization, dramatically compresses cycle time by prioritizing the most informative compounds for synthesis, directly addressing the bottleneck of low-throughput synthesis and assay steps.

CLOSED-LOOP DISCOVERY

Key Characteristics of the DMTA Cycle

The Design-Make-Test-Analyze (DMTA) cycle is the central engine of modern drug discovery, integrating computational design, chemical synthesis, biological assay, and data analysis into a continuous, iterative optimization loop.

Iterative Hypothesis Refinement

The DMTA cycle is fundamentally a hypothesis-driven process. Each round begins with a specific molecular hypothesis (e.g., 'adding a methyl group at this position will increase potency'). The cycle's output is not just a better molecule, but validated knowledge that refines the team's understanding of structure-activity relationships (SAR). This transforms drug discovery from a random screening exercise into a systematic, knowledge-building engine.

Parallelization and Bottleneck Management

A key operational characteristic is the strategic parallelization of sub-processes to compress cycle time. While one batch of compounds is being assayed, the next is being synthesized, and the subsequent round is being designed based on incoming data. The rate-limiting step shifts between design, synthesis, and testing depending on the project phase. Modern DMTA implementations use predictive models to triage compounds, ensuring only the most informative molecules consume scarce synthesis and assay resources.

Multiparameter Optimization (MPO)

The 'Analyze' phase rarely evaluates a single endpoint. It integrates a multiparameter profile including:

Potency against the primary target
Selectivity against anti-targets
ADMET properties (clearance, permeability, hERG inhibition)
Physicochemical properties (solubility, logD) The goal is to find a Pareto-optimal balance, where improving one property does not catastrophically degrade another. This requires visualizing high-dimensional data to make trade-off decisions.

Data Standardization and FAIR Principles

The cycle's efficiency is entirely dependent on seamless data flow. All assay results, chemical structures, and metadata must be instantly Findable, Accessible, Interoperable, and Reusable (FAIR). This requires a centralized informatics platform that registers compounds, captures raw and processed data, and links results to specific experimental conditions. Without this, the 'Analyze' phase becomes a manual data-wrangling bottleneck, breaking the closed-loop feedback.

Integration of AI at Every Phase

Modern DMTA cycles embed machine learning at each stage:

Design: Generative models propose novel structures with predicted MPO profiles.
Make: AI-driven retrosynthesis planning tools rank synthetic routes by probability of success.
Test: Computer vision and NLP automate the extraction of results from assay instruments and reports.
Analyze: Active learning algorithms select the next batch of compounds to test, maximizing information gain per experiment.

Cycle Time Compression as a KPI

The primary metric for a DMTA cycle is time from hypothesis to validated result. Leading organizations track this in days, not weeks. Compression is achieved through:

Automated synthesis (flow chemistry, parallel synthesis)
High-throughput screening (miniaturized assays)
Predictive modeling to replace low-value assays The faster the cycle, the more hypotheses can be tested per unit time, directly correlating with the probability of finding a clinical candidate.

DMTA CYCLE FAQ

Frequently Asked Questions

Clear, technical answers to common questions about the Design-Make-Test-Analyze cycle, the iterative engine of modern drug discovery.

The Design-Make-Test-Analyze (DMTA) cycle is the iterative, closed-loop workflow that forms the operational backbone of modern drug discovery, systematically refining molecular candidates through successive rounds of computational design, chemical synthesis, biological assay, and data analysis. Each cycle begins with the Design phase, where medicinal chemists and computational models propose new molecular structures based on prior data and project hypotheses. The Make phase involves synthesizing these designed compounds, often leveraging parallel chemistry or automated platforms. The Test phase subjects the purified compounds to a cascade of biological assays, measuring potency, selectivity, and ADMET properties. Finally, the Analyze phase interprets the resulting data, updating structure-activity relationship (SAR) models and informing the design hypotheses for the next iteration. The goal is to converge rapidly on a clinical candidate by compressing the time between hypothesis generation and experimental validation.

Enabling Efficiency, Speed & Accuracy

Intelligent Analysis, Decision & Execution

We build AI systems for teams that need search across company data, workflow automation across tools, or AI features inside products and internal software.

Talk to Us

Search across company data

Give teams answers from docs, tickets, runbooks, and product data with sources and permissions.

Useful when people spend too long searching or get different answers from different systems.

Enterprise searchRAGPermissions

Automate internal workflows

Use AI to route work, draft outputs, trigger actions, and keep approvals and logs in place.

Useful when repetitive work moves across multiple tools and teams.

AI agentsWorkflow automationGovernance

Add AI to products and internal tools

Build assistants, guided actions, or decision support into the software your team or customers already use.

Useful when AI needs to be part of the product, not a separate tool.

AI integrationDecision supportModel routing

Core Concepts

Related Terms

Explore the foundational computational and experimental concepts that constitute the iterative Design-Make-Test-Analyze (DMTA) cycle in modern drug discovery.

Active Learning Loop

An iterative design cycle where a predictive model identifies the most informative molecules to synthesize and assay next. By strategically selecting compounds that maximize learning—balancing exploitation of high-scoring regions with exploration of uncertain chemical space—the loop rapidly converges on optimal candidates with minimal experimental cost.

3-5x

Faster hit-to-lead

Multi-Objective Molecular Optimization

The simultaneous optimization of multiple, often conflicting, drug properties within the DMTA cycle. Using Pareto frontier algorithms, teams balance potency against solubility, bioavailability against metabolic stability, and efficacy against synthetic accessibility. This prevents the common failure mode of optimizing a single parameter at the expense of a viable drug profile.

Synthetic Accessibility Score

A quantitative metric that estimates the ease with which a computationally designed molecule can be synthesized in the lab. Derived from retrosynthetic complexity or fragment frequency analysis, this score acts as a critical filter in the 'Make' phase, ensuring that generative models do not propose theoretically ideal but practically impossible structures.

ADMET Property Prediction

The use of machine learning models to forecast a molecule's absorption, distribution, metabolism, excretion, and toxicity profiles early in the design cycle. By front-loading these predictions, the DMTA loop eliminates candidates with fatal pharmacokinetic flaws before costly synthesis and biological assays, dramatically reducing late-stage attrition.

Chemical Space Exploration

The systematic navigation of the vast theoretical universe of synthesizable molecules to identify regions with a high probability of containing viable drug candidates. This concept frames the 'Design' phase, where generative models and search algorithms traverse 10^60 possible compounds to locate islands of biological activity.

Bayesian Optimization for Molecules

A sequential model-based optimization strategy that efficiently guides the DMTA cycle. It constructs a probabilistic surrogate model of the structure-activity landscape and uses an acquisition function to suggest the next batch of molecules for synthesis, explicitly balancing the trade-off between testing known good candidates and exploring unknown regions.

About the author

Prasad Kumkar

CEO & MD, Inference Systems

Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.

His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.

Limited slotsGet a Free AI Consultation

How We Work

Custom AI workflows for your Business

One-fit-all AI don't work for modern businesses. At Inferensys, we aim to understand your business & custom requirements; which we use to define most efficient agentic workflows, the data, and the tools for your business.